In a reader survey, researchers and core lab staff share how they think cores are doing.
GreenLight Biosciences is using a proprietary cell-free RNA production technology to develop RNA-based products for the agricultural market.
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Researchers are working on RNA inference-based pesticides for crops, according to Digital Trends.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
The investment bank began coverage with an Outperform rating, noting that Horizon's recent acquisition of Dharmacon is highly complementary and synergistic.
Researchers from the Broad Institute and Novartis used RNA interference to generate catalogs of genes that cancer cells rely on to grow and survive.
The US Environmental Protection Agency has approved an RNAi-based insecticide, according to the Atlantic.
Researchers described the development and testing of layered double hydroxide nanosheets as carriers for RNAi molecules in agriculture.
An Australian team has developed a method to spray double-stranded RNA on plants to make them resistant to pests, Technology Review reports.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.
